{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-013613","form_type":"8-K","ticker":"PIII","cik":"0001832511","company_name":"P3 Health Partners Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.837984+00:00","generated_at":"2026-06-04T06:29:11.813148+00:00","sec_items":["1.01","2.02","2.03","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"P3 Health reports FY23 revenue $1.27B (+21% YoY); affirms 2024 Adj. EBITDA guidance $20M-$40M","bullets":["Total revenue $1.27B for FY2023 (+21% YoY); net loss $186.4M vs $1.56B prior year.","Medical margin $135.1M (+118% YoY); Adjusted EBITDA loss $85.5M (improved from $127.9M).","Affirms 2024 guidance: at-risk members 125k-135k, revenue $1.45B-$1.55B, Adj. EBITDA $20M-$40M.","P3 LLC entered $25M unsecured promissory note (17.5% interest) from VBC Growth SPV 2 for growth pipeline.","Note subordinated to existing term loan; related-party transaction approved by independent committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-013613","json":"https://secwatch.observer/filing/0001628280-24-013613.json","markdown":"https://secwatch.observer/filing/0001628280-24-013613.md","text":"https://secwatch.observer/filing/0001628280-24-013613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832511/000162828024013613/0001628280-24-013613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832511/000162828024013613/piii-20240322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:29:11.813148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe55e1e6680d89ca295dc7854ca5c704830e4f3e","claim":"P3 Health Partners Inc. incurred loan of up to $25.0 million with VBC Growth SPV 2, LLC at 17.5% per annum maturing September 30, 2027.","evidence_excerpt":"of independent, disinterested directors of the Company. Promissory Note The Promissory Note was issued by P3 LLC to VBC 2 on March 22, 2024, and provides for funding of up to $25.0 million, available for draw by P3 LLC in two tranches, as follows: (i) a first tranche of $10.0 million available to P3 LLC upon the Effective Date, and (ii) a second tranche of $15.0","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832511/000162828024013613/0001628280-24-013613-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"up to $25.0 million"},{"label":"Counterparty","value":"VBC Growth SPV 2, LLC"},{"label":"Rate","value":"17.5% per annum"},{"label":"Maturity","value":"September 30, 2027"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"9c51fd03a7e4d4e24b45bd24eb520dd510641c1d","claim":"P3 Health Partners Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $346.9 million, net income Net loss was $69.1 million. Guidance reaffirmed.","evidence_excerpt":"for the P3 model is as high as ever and that our demonstrated ability to bend the cost curve is driving this demand.” Fourth Quarter 2023 Financial Results • Total revenue was $346.9 million, an increase of 34% compared to $258.2 million in the fourth quarter of the prior year • Capitated revenue was $342.8 million, an increase of 35% compared to $254.0 million in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832511/000162828024013613/0001628280-24-013613-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$346.9 million"},{"label":"Net income","value":"Net loss was $69.1 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}